Benhnia Mohammed Rafii-El-Idrissi, McCausland Megan M, Moyron Juan, Laudenslager John, Granger Steven, Rickert Sandra, Koriazova Lilia, Kubo Ralph, Kato Shinichiro, Crotty Shane
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
J Virol. 2009 Feb;83(3):1201-15. doi: 10.1128/JVI.01797-08. Epub 2008 Nov 19.
Antibody neutralization is an important component of protective immunity against vaccinia virus (VACV). Two distinct virion forms, mature virion and enveloped virion (MV and EV, respectively), possess separate functions and nonoverlapping immunological properties. In this study we examined the mechanics of EV neutralization, focusing on EV protein B5 (also called B5R). We show that neutralization of EV is predominantly complement dependent. From a panel of high-affinity anti-B5 monoclonal antibodies (MAbs), the only potent neutralizer in vitro (90% at 535 ng/ml) was an immunoglobulin G2a (IgG2a), and neutralization was complement mediated. This MAb was the most protective in vivo against lethal intranasal VACV challenge. Further studies demonstrated that in vivo depletion of complement caused a >50% loss of anti-B5 IgG2a protection, directly establishing the importance of complement for protection against the EV form. However, the mechanism of protection is not sterilizing immunity via elimination of the inoculum as the viral inoculum consisted of a purified MV form. The prevention of illness in vivo indicated rapid control of infection. We further demonstrate that antibody-mediated killing of VACV-infected cells expressing surface B5 is a second protective mechanism provided by complement-fixing anti-B5 IgG. Cell killing was very efficient, and this effector function was highly isotype specific. These results indicate that anti-B5 antibody-directed cell lysis via complement is a powerful mechanism for clearance of infected cells, keeping poxvirus-infected cells from being invisible to humoral immune responses. These findings highlight the importance of multiple mechanisms of antibody-mediated protection against VACV and point to key immunobiological differences between MVs and EVs that impact the outcome of infection.
抗体中和作用是抗痘苗病毒(VACV)保护性免疫的重要组成部分。两种不同的病毒粒子形式,即成熟病毒粒子和包膜病毒粒子(分别为MV和EV),具有各自独立的功能和不重叠的免疫特性。在本研究中,我们研究了EV中和作用的机制,重点关注EV蛋白B5(也称为B5R)。我们发现,EV的中和作用主要依赖补体。在一组高亲和力抗B5单克隆抗体(MAb)中,唯一在体外具有强效中和作用的(在535 ng/ml时达到90%)是免疫球蛋白G2a(IgG2a),且中和作用是由补体介导的。该MAb在体内对致死性鼻内VACV攻击的保护作用最强。进一步研究表明,体内补体的消耗导致抗B5 IgG2a保护作用丧失超过50%,直接证实了补体对抵抗EV形式的保护作用的重要性。然而,保护机制并非通过消除接种物实现的无菌免疫,因为病毒接种物由纯化的MV形式组成。体内疾病的预防表明感染得到了快速控制。我们进一步证明,抗体介导的对表达表面B5的VACV感染细胞的杀伤是补体结合抗B5 IgG提供的第二种保护机制。细胞杀伤非常有效,且这种效应功能具有高度的同种型特异性。这些结果表明,通过补体介导的抗B5抗体定向细胞裂解是清除感染细胞的强大机制,可使痘病毒感染的细胞不会对体液免疫反应隐身。这些发现突出了抗体介导的抗VACV保护的多种机制的重要性,并指出了MV和EV之间影响感染结果的关键免疫生物学差异。